Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Prepaid Assets: 2022-2025

Historic Prepaid Assets for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $28.1 million.

  • NewAmsterdam Pharma Co N.V's Prepaid Assets rose 85.37% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 85.37%. This contributed to the annual value of $24.3 million for FY2024, which is 282.78% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Prepaid Assets stood at $28.1 million for Q3 2025, which was down 8.52% from $30.7 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Prepaid Assets high stood at $30.7 million for Q2 2025, and its period low was $5,769 during Q2 2023.
  • Its 3-year average for Prepaid Assets is $15.0 million, with a median of $14.6 million in 2024.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Prepaid Assets crashed by 38.14% in 2023 and then surged by 253,739.49% in 2024.
  • NewAmsterdam Pharma Co N.V's Prepaid Assets (Quarterly) stood at $10.3 million in 2022, then plummeted by 38.14% to $6.3 million in 2023, then soared by 282.78% to $24.3 million in 2024, then surged by 85.37% to $28.1 million in 2025.
  • Its last three reported values are $28.1 million in Q3 2025, $30.7 million for Q2 2025, and $8.8 million during Q1 2025.